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ABSTRACT
Background    123I-metaiodobenzylguanidine (MIBG) 
myocardial scintigraphy and 123I-FP-CIT dopamine 
transporter single photon emission computed tomog-
raphy (DAT-SPECT) provide specific information that 
distinguish Parkinson’s disease (PD) from parkinsonian 
syndromes other than PD (non-PD), including atypical 
parkinsonian disorder (APD) and non-PD other than 
APD (nPD-nAPD). The purpose of this study was to 
determine whether combining DAT-SPECT and MIBG 
myocardial scintigraphy using multiparametric scoring 
system (MSS) could improve diagnostic test accuracy 
in discriminating PD from APD or discriminating PD 
from nPD-nAPD.
Methods    A total of 52 patients, including 36 PD, eight 
APD and eight nPD-nAPD, underwent both MIBG 
myocardial scintigraphy and DAT-SPECT, were eval-
uated. The heart-to-mediastinum (H/M) ratios (early 
and delayed), washout-rate (WR), the average (Ave) and 
asymmetry index (AI) of specific binding ratio (SBR) 
were calculated. Cutoff values were determined, using 
ROC analysis, for discriminating PD from APD and for 
discriminating PD from nPD-nAPD, on five parameters. 
All cases were scored as either 1 (PD) or 0 (nPD-nAPD 
or APD) for each parameter according to its threshold 
in each discrimination. These individual scores were 
summed for each case, yielding a combined score to ob-
tain a cutoff value for the MSS in each discrimination. 
Results    For discriminating PD from nPD-nAPD, the 
highest accuracy was 80% at a cutoff value of 19% for 
the WR and a cut off value of 2 improved diagnostic 
accuracy to 84% for MSS. For discriminating PD from 
APD, the highest accuracy was 86% at a cutoff value 
of 2.8 for the H/M ratio (late) and a cut off value of 2 
showed diagnostic accuracy of 86% for MSS.
Conclusion    A MSS has comparable or better accuracy 
compared to each parameter of MIBG myocardial scin-
tigraphy and DAT-SPECT in distinguishing PD from 
nPD-nAPD or distinguishing PD from APD.
Key words    123I-FP-CIT; 123I-MIBG; Parkinson’s dis-
ease; combined analysis
Parkinson’s disease (PD) is characterized by the degen-
eration of both dopaminergic and nondopaminergic neu-
rons with neuronal intracytoplasmic inclusions known as 
Lewy bodies. Clinically, PD is characterized by resting 
tremor, muscle rigidity, bradykinesia and postural insta-
bility. Clinical differentiation of PD from parkinsonian 
syndromes other than PD (non-PD), such as atypical par-
kinsonian disorder (APD), including multiple system at-
rophy (MSA), progressive supranuclear palsy (PSP) and 
corticobasal degeneration (CBD), or non-PD other than 
APD (nPD-nAPD), including vascular parkinsonism and 
drug-induced parkinsonism, is often difficult because of 
their overlapping clinical features. Improving diagnostic 
accuracy is critical for the differentiation of PD and non-
PD because their prognoses are very different, and the 
choice of treatment strategy is extremely important. 
 Molecular imaging techniques using single photon 
emission computed tomography (SPECT) or positron 
emission tomography (PET) offer a variety of tools for 
diagnosing patients with parkinsonian syndromes.1–3 
Dopamine transporter SPECT (DAT-SPECT) using N-v-
fluoro-propyl-2b-carbomethoxy-3b-(4-123I-iodophenyl)nor-
tropane (123I-FP-CIT ) is a sensitive method for detection of 
presynaptic dopamine neuronal dysfunction and has pres-
ently become an essential method for evaluating parkin-
sonism.4 On the other hand, 123I-metaiodobenzylguanidine 
(MIBG) myocardial scintigraphy traces uptake and 
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transport both in noradrenaline presynaptic sympathetic 
nerve terminals and in subsequent vesicular storage. 
A reduction of MIBG uptake indicates postganglionic 
sympathetic dysfunction.5
 DAT-SPECT allows differentiation of degenerative 
parkinsonian syndromes from nPD-nAPD that are not 
associated with dopaminergic deficit, such as essen-
tial tremor, vascular parkinsonism and drug-induced 
parkinsonism.6 However, DAT-SPECT alone does not 
differentiate the various types of degenerative parkinso-
nian syndromes including APD and PD with sufficient 
accuracy.7, 8 Whereas, cardiac MIBG uptake is reduced 
in patients with Lewy body diseases such as PD, as well 
as dementia with Lewy bodies, and MIBG myocardial 
scintigraphy can also help to differentiate PD from 
n-PD.9–12
 However, all these molecular imaging techniques are 
limited in terms of their test accuracy. The use of DAT-
SPECT or MIBG myocardial scintigraphy as stand-
alone diagnostic mean is currently not recommended 
for differentiating PD from n-PD.8 The usefulness of 
the combination of DAT-SPECT and MIBG myocardial 
scintigraphy has been reported in patients with parkin-
sonian syndrome.13–23
 A multiparametric scoring system (MSS) is an 
original simple method using summed scores obtained 
by each parameter according to its threshold for dis-
criminating two groups. In our previous studies, MSS 
has improved accuracy compared to each parameter 
of multiple physiologic MR studies including diffusion 
weighted imaging, perfusion weighted imaging, and MR 
spectroscopy in differentiating tumor progression from 
radiation change.24 Furthermore, MSS also has improved 
accuracy compared to each parameter of 123I-FP-CIT 
dopamine transporter single photon emission computed 
tomography and Neuromelanin-MRI in differentiating 
Parkinson’s disease from non-degenerative parkinso-
nian syndrome.25 Therefore, this scoring system can 
potentially offset an incorrect classification based on 
any single parameter and is expected to be a more useful 
indicator than any single parameters.
 We performed a retrospective study of patients with 
parkinsonian syndrome to determine whether combining 
DAT-SPECT and MIBG myocardial scintigraphy using 
multiparametric scoring system (MSS) could improve 
diagnostic test accuracy in discriminating PD from APD 
or discriminating PD from nPD-nAPD.
MATERIALS AND METHODS
Patients
Fifty-two patients, who underwent both MIBG myocar-
dial scintigraphy and DAT-SPECT for a differential di-
agnosis between PD and other parkinsonian syndromes 
were consecutively enrolled in this retrospective study, 
which was evaluated between March 2014 and April 
2017. All of 52 patients were confirmed to the results of 
both MIBG myocardial scintigraphy and DAT-SPECT. 
Thirty-six of 52 patients were diagnosed with probable 
PD according to the criteria of the United Kingdom 
Brain Bank and prospective follow-up including positive 
response to dopaminergic medications. Patients with 
PD were assigned to groups either mild to moderate-PD 
(MM-PD) or severe-PD (S-PD) on the basis of Hoehn 
and Yahr staging.26 Also, MM-PD comprised stages I 
and II (n =16), and S-PD comprised stages III, IV and 
V (n = 20). Furthermore, no patients were diagnosed 
with dementia with Lewy bodies in 52 patients. Eight 
of 52 patients were diagnosed with APD and eight of 
52 patients were diagnosed with nPD-nAPD. APD 
comprised PSP (n = 4), MSA (n = 3) and CBD (n = 1) 
and nPD-nAPD comprised Alzheimer disease (n = 3), 
essential tremor (n = 1), vascular parkinsonian syndrome 
(n = 2), organophosphorus poisoning (n = 1) and folic 
acid deficiency (n = 1). Diagnosis of MSA, PSP or CBD 
was made based on the accepted diagnostic criteria 
for each disease.27–29 None of the patients had diabetes 
mellitus or cardiac disease, and none was taking any 
medication known to influence uptake of 123I-FP-CIT or 
to affect MIBG accumulation.30, 31 Clinical characteris-
tics of the four groups; nPD-nAPD, APD, MM-PD and 
S-PD, are shown in Table 1. The institutional review 
board of Tottori Prefectural Central Hospital approved 
this retrospective study (approval number: 2017-8), and 
the requirement for written informed consent of the 
participants was waived by the review board due to the 
retrospective nature of the study.
Image acquisition and analysis
123I-MIBG myocardial scintigraphy
The patient received an intravenous injection of 111 
MBq of 123I-MIBG and static planar images of the 
chest were acquired 30 minutes and 3 hours later for 
10 minutes in a 512 × 512 matrix of 0.67 mm pixels by 
use of a dual-head gamma camera with a low-medium 
energy, general purpose collimator (Symbia E; Siemens, 
Erlangen, Germany). Relative organ uptake was deter-
mined by setting the regions of interest (ROI) on the 
anterior view. The heart-to-mediastinum (H/M) ratio 
was calculated by dividing the count density of the left 
ventricular ROI by that of the mediastinal ROI. For the 
comparison study, H/M ratios calculated from the ROI 
counts both in early and delayed images were used for 
analysis. In this study, we also calculated washout rate 
(WR), which is an index of the rate at which MIBG is 
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Table 1. Clinical characteristics of nPD-nAPD, APD, MM-PD and S-PD patients
nPD-nAPD APD MM-PD S-PD
Number 8 8 16 20
Age (years), range 65–86 65–83 53–82 62–87
Age (years), mean ± SD 73 ± 8 71 ± 6 66 ± 9 79 ± 8
Female/male 3/5 4/4 8/8 11/9
Hoehn and Yahr stage / / I: 9, II: 7 III: 12, IV: 5, V: 3
Duration (years), mean ± SD 2.3 ± 2.2 3.7 ± 2.1 1.2 ± 1.3 2.4 ± 2.5
APD, atypical parkinsonian disorder; MM, mild to moderate; nPD-nAPD, parkinsonian syndromes other than PD or APD; PD, 
Parkinson’s disease; S, severe. 
washed out between the early image and the delayed 
image, according the following equation;
WR = [(early heart uptake-early mediastinum uptake) 
– (delayed heart uptake-delayed mediastinum uptake)] / 
(early heart uptake-early mediastinum uptake) × 100 (%)
DAT-SPECT imaging
The patients received an intravenous injection of 167 
MBq of 123I-FP CIT, and SPECT images of the head 
were acquired 3 hours later for 20 min (2.5 min × 8 
repeats × 1 cycle) in a 128 × 128 matrix of 2.7-mm 
pixels by use of a dual-head gamma camera with 
a low-medium energy, general purpose collimator 
(Symbia E; Siemens, Erlangen, Germany). SPECT im-
ages were reconstructed with the iterative algorithm; 
the ordered subset expectation maximization and spe-
cific binding ratio (SBR) were defined as the uptake 
ratio of (striatum-whole brain)/ whole brain by using 
DatView (Nihon Medi-Physics, Tokyo, Japan) based 
on Tossici-Bolt’s method.32 
The average of SBR (Ave-SBR) was calculated using the 
following equations;
Ave-SBR = (right SBR + left SBR)/2 × 100[%].
The asymmetry index of SBR (AI-SBR) was also calcu-
lated using the following equations:
AI-SBR (absolute value) = (right SBR – left SBR) × 2/ 
(right SBR + left SBR) × 100[%].
Statistical analysis
Differences among four groups; nPD-nAPD, APD, 
MM-PD and S-PD groups in the H/M ratio (early), H/M 
ratio (delayed) and WR on MIBG myocardial scintigra-
phy were statistically analyzed using the Kruskal-Wallis 
test followed by the Mann-Whitney U test. Furthermore, 
difference among four groups in the Ave-SBR and AI-
SBR (absolute value) on DAT SPECT were statistically 
analyzed using the same test. 
Evaluations of five parameters for two statistical discrimina-
tions
We statistically evaluated two statistical discriminations; 
the discrimination of PD group (MM-PD group plus 
S-PD group) from nPD-nAPD group and the discrimi-
nation of PD group from APD group. In each statistical 
discrimination, cutoff values that provided the best com-
bination of sensitivity and specificity for each parameter 
were selected using receiver operating characteristic 
(ROC) analysis. Cutoff values were determined using 
the Youden index. We determined the accuracy, sensi-
tivity, specificity, positive predictive value, and negative 
predictive value of each parameter using Chi-square 
analysis. Also, as described below, both MSS and simple 
combined analysis were performed in each of the two 
statistical discriminations. 
Evaluations of MSS for two statistical discriminations
For two statistical discriminations; discriminating PD 
from nPD-nAPD and PD from APD, we used all five 
parameters, including H/M ratio (early), H/M ratio (de-
layed), WR, Ave-SBR and AI-SBR. For discriminating 
PD from nPD-nAPD, all cases were scored as either 1 
(PD) or 0 (nPD-nAPD) for each parameter according to 
its threshold. For discriminating PD from APD, all cases 
were scored as either 1 (PD) or 0 (APD) for each param-
eter according to its threshold. In each of the two dis-
criminations, these individual scores were summed for 
each subject, yielding a combined score for each case. 
ROC analysis was performed to obtain a cutoff value for 
the scoring system in each of the two discriminations. 
Finally, we calculated the accuracy, sensitivity, speci-
ficity, positive predictive value, and negative predictive 
value of the MSS using Chi-square analysis in each of 
the two discriminations. 
Evaluations of simple combined analysis for two statistical 
discriminations
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Table 2. The parameters in nPD-nAPD, APD, MM-PD and S-PD
 nPD-nAPD APD MM-PD S-PD P value
range (median) range (median) range (median) range (median) (Kruskal-Wallis Test)
MIBG
H/M ratio (E) 2.13–4.43 (2.51) 1.56–3.82 (2.83) 1.53–3.27 (2.31) 1.18–3.27 (1.66) P < 0.001
H/M ratio (D) 1.98–5.18 (2.66) 1.28–4.45 (3.12) 1.23–3.42 (2.24) 1.03–3.42 (1.59) P < 0.001
WR (%) 1.9–31.7 (16.1) 4.5–79.4 (32.9) 10–78.4 (27.9) 9.6–93.7 (49) P < 0.001
DAT-SPECT
Ave SBR (%) 0.59–8.46 (6.15) 1.33–5.72 (3.87) 2.48–7.34 (4.65) 1.52–6.01 (2.59) P < 0.005
AI SBR (%) 3.5–29.2 (5.88) 1.8–82.7 (27.25) 1.68–37.4 (17.35) 0.4–56.78 (16.47) P = 0.133
AI, asymmetry index; APD, atypical parkinsonian disorder; Ave, average; D, delayed; DAT-SPECT, 123I-FP-CIT dopamine transporter 
single photon emission computed tomography; E, early; H/M, heart to mediastinum; 123I-FP-CIT, N-v-fluoro-propyl-2bcarbomethoxy-3b-
(4-123I-iodophenyl)nortropane; MIBG, 123I-metaiodobenzylguanidine; MM, mild to moderate; nPD-nAPD, parkinsonian syndromes other 
than PD or APD; PD, Parkinson’s disease; S, severe; SBR, specific binding ratio; WR, washout rate.
For two statistical discriminations, we adapted a param-
eter with the best accuracy in each DAT-SPECT (Ave-
SBR and AI-SBR) and MIBG myocardial scintigraphy 
[H/M ratio (early), H/M ratio (delayed) and WR] respec-
tively; total two parameters were selected in each of the 
two discriminations. Combined analysis using two pa-
rameters, according to their thresholds, was performed 
in each of the two statistical discriminations. Finally, we 
calculated the accuracy, sensitivity, specificity, positive 
predictive value, and negative predictive value of the 
combined analysis using Chi-square analysis in each of 
the two discriminations. 
 All statistical analyses were performed with EZR 
(Saitama Medical Center, Jichi Medical University, 
Saitama, Japan), which is a graphical user interface for 
R (The R Foundation for Statistical Computing, Vienna, 
Austria).33 P < .05 was considered indicative of a signifi-
cant difference.  
RESULTS
H/M ratio (early), H/M ratio (delayed), WR, Ave-SBR 
and AI-SBR in nPD-nAPD, APD, MM-PD and S-PD 
are shown in Table 2. Scatterplots of all these parame-
ters are shown in Fig. 1. 
 For the H/M ratio (early), H/M ratio (delayed) and 
WR, significant differences were observed among the 4 
groups; nPD-nAPD, APD, MM-PD and S-PD groups. 
Significant differences were observed between nPD-
nAPD and S-PD and between MM-PD and S-PD in 
H/M ratio (early and delayed) and WR. For the Ave-
SBR, significant differences were observed among the 4 
groups. Significant differences were observed between 
MM-PD and S-PD. For the AI-SBR (absolute value), 
no significant differences were observed among the 4 
groups.
Evaluations of five parameters for two statistical discrimina-
tions
As for discriminating PD from nPD-nAPD, ROC anal-
yses showed that for the H/M ratio (early), the accuracy 
was 68% at a cutoff value of 2.1. For the H/M ratio 
(delayed), the accuracy was 70% at a cutoff value of 1.9. 
For the WR, the accuracy was 80% at a cutoff value of 
19%. For the Ave-SBR, the accuracy was 70% at a cut-
off value of 4.29%. For the AI-SBR, the accuracy was 
59% at a cutoff value of 16.9%. The accuracy, sensitivity, 
specificity, positive predictive value and negative predic-
tive value of each adapted parameter in differentiating 
PD from nPD-nAPD are summarized in Table 3.
 As for discriminating PD from APD, ROC analyses 
showed that for the H/M ratio (early), the accuracy was 
82% at a cutoff value of 2.51. For the H/M ratio (delayed), 
the accuracy was 86% at a cutoff value of 2.8. For the 
WR, the accuracy was 80% at a cutoff value of 22%. For 
the Ave-SBR, the accuracy was 57% at a cutoff value of 
3.31%. For the AI-SBR, the accuracy was 77% at a cut-
off value of 21.8%. The accuracy, sensitivity, specificity, 
positive predictive value and negative predictive value of 
each adapted parameter in differentiating PD from APD 
are summarized in Table 4.
Evaluations of MSS for two statistical discriminations
For the evaluation of MSS, we used five parameters, 
including H/M ratio (early), H/M ratio (delayed), WR, 
Ave-SBR and AI-SBR. 
 As for discriminating PD from nPD-nAPD, the 
scoring of each adapted parameter is shown in Table 3. 
For the MSS, the accuracy for discriminating PD from 
nPD-nAPD was 84% at a cutoff value of 2; PD diag-
nosis was indicated by total score 2, 3, 4 or 5 and nPD-
nAPD diagnosis was indicated by total score 0 or 1. The 
accuracy, sensitivity, specificity, positive predictive value 
and negative predictive value of MSS in differentiating 
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Fig. 1. Scatterplots of the H/M ratio (early), 
H/M ratio (delayed), WR, Ave-SBR and 
AI-SBR. ACC, accuracy; AI, asymmetry 
index; APD, atypical parkinsonian disorder; 
Ave, average; CO, cutoff; H/M, heart to 
mediastinum ratio; MM, mild to moderate; 
nPD-nAPD, parkinsonian syndromes other 
than PD or APD; PD, Parkinson’s disease; 
S, severe; SBR, specific binding ratio; WR, 
washout rate.
Table 3. The diagnostic tests of each adapted parameter, of a MSS and of a simple combined analysis for dis-
criminating PD from nPD-nAPD
AUC Cutoff value ACC SEN SPE PPV NPV P value Classified as PD Classified as nPD-nAPD
MIBG
H/M ratio (E) 0.78 2.1 68% 61% 100% 100% 36% P < 0.001 ≤ 2.1: score 1 > 2.1: score 0
H/M ratio (D) 0.84 1.9 70% 64% 100% 100% 38% P < 0.001 ≤ 1.9: score 1 > 1.9: score 0
WR 0.89 19% 80% 83% 63% 91% 45% P < 0.001 ≥ 19%: score 1 < 19%: score 0
DAT-SPECT
Ave-SBR 0.68 4.29% 70% 69% 75% 93% 86% P < 0.05 ≤ 4.29%: score 1 > 4.29%: score 0
AI-SBR 0.58 16.9% 59% 53% 88% 95% 29% P = 0.05 ≥ 16.9%: score 1 < 16.9%: score 0
MSS 0.9 2 84% 83% 88% 97% 54% P < 0.001 score 2, 3, 4, 5 score 0, 1
SCA NA WR 19% Ave-SBR 4.29% 70% 64% 100% 100% 38% P < 0.001
≥ WR 19% and 
≤ Ave-SBR 4.29%
< WR 19% or
> Ave-SBR 4.29%
ACC, accuracy; AI, asymmetry index; AUC, area under the curve; Ave, average; D, delayed; DAT-SPECT, 123I-FP-CIT dopamine 
transporter single photon emission computed tomography; E, early; H/M, heart to mediastinum ratio; 123I-FP-CIT, N-v-fluoro-propyl-2b-
carbomethoxy-3b-(4-123I-iodophenyl)nortropane; L, late; MIBG,123I-metaiodobenzylguanidine; MSS, multiparametric scoring system; 
NA, not applicable; nPD-nAPD, parkinsonian syndromes other than PD or APD; NPV, negative predictive value; PD, Parkinson’s dis-
ease; PPV, positive predictive value; SBR, specific binding ratio; SCA simple combined analysis; SEN, sensitivity; SPE, specificity; WR, 
washout rate.
H/M ratio (E) scoring: H/M ratio (E) ≤ 2.1, score 1; H/M ratio (E) > 2.1, score 0. H/M ratio (D) scoring: H/M ratio (D) ≤ 1.9, score 1; 
H/M ratio (D) > 1.9, score 0. WR scoring: WR ≥ 19%, score 1; WR < 19%, score 0. Ave-SBR scoring: Ave-SBR ≤ 4.29%, score 1; Ave-
SBR > 4.29%, score 0. AI-SBR scoring: AI-SBR ≥ 16.9%, score 1; AI-SBR < 16.9%, score 0. MSS: Total score 2, 3, 4 or 5, classified as 
PD; Total score 0 or 1, classified as nPD-nAPD. SCA: ≥ WR 19% and ≤ Ave-SBR 4.29%, classified as PD; < WR 19% or > Ave-SBR 4.29%, 
classified as nPD-nAPD.
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Table 4. The diagnostic tests of each adapted parameter, of a MSS and of a simple combined analysis for dis-
criminating PD from APD
AUC Cutoff value ACC SEN SPE PPV NPV P value Classified as PD Classified as nPD-nAPD
MIBG
H/M ratio (E) 0.80 2.51 82% 83% 75% 94% 50% P < 0.001 ≤ 2.51: score 1 > 2.51: score 0
H/M ratio (D) 0.81 2.8 86% 92% 63% 92% 63% P < 0.001 ≤ 2.8: score 1 > 2.8: score 0
WR 0.80 22% 80% 83% 63% 91% 45% P < 0.001 ≥ 22%: score 1 < 22%: score 0
DAT-SPECT
Ave-SBR 0.54 3.31% 57% 53% 75% 90% 26% P = 0.25 ≤ 3.31%: score 1 > 3.31%: score 0
AI-SBR 0.70 21.8% 77% 81% 63% 91% 42% P < 0.05 ≤ 21.8%: score 1 > 21.8%: score 0
MSS 0.86 2 86% 92% 63% 92% 63% P < 0.001 score 2, 3, 4, 5 score 0, 1
SCA NA
H/M ratio (D) 2.8
AI-SBR 21.8%
80% 78% 88% 97% 47% P < 0.001
≤ H/M ratio (D) 2.8 
and
≤ AI-SBR 21.8% 
> H/M ratio (D) 2.8 
or 
> AI-SBR 21.8%
ACC, accuracy; AI, asymmetry index; APD, atypical parkinsonian disorder; AUC, area under the curve; Ave, average; D, delayed; DAT-
SPECT, 123I-FP-CIT dopamine transporter single photon emission computed tomography; E, early; H/M, heart to mediastinum ratio; 
123I-FP-CIT, N-v-fluoro-propyl-2b-carbomethoxy-3b-(4-123I-iodophenyl) nortropane; L, late; MIBG, 123I-metaiodobenzylguanidine; MSS, 
multiparametric scoring system; NA, not applicable; NPV, negative predictive value; PD, Parkinson’s disease; PPV, positive predictive 
value; SBR, specific binding ratio; SCA, simple combined analysis; SEN, sensitivity; SPE, specificity; WR, washout rate.
H/M ratio (E) scoring: H/M ratio (E) ≤ 2.51, score 1; H/M ratio (E) > 2.51, score 0. H/M ratio (D) scoring: H/M ratio (D) ≤ 2.8, score 1; 
H/M ratio (D) > 2.8, score 0. WR scoring: WR ≥ 22%, score 1; WR < 22%, score 0. Ave-SBR scoring: Ave-SBR ≤ 3.31%, score 1; Ave-
SBR > 3.31%, score 0. AI-SBR scoring: AI-SBR ≤ 21.8%, score 1; AI-SBR > 21.8%, score 0. MSS: Total score 2, 3, 4 or 5, classified as 
PD; Total score 0 or 1, classified as nPD-nAPD. SCA: ≤ H/M ratio (L) 2.8 and ≤ AI-SBR 21.8%, classified as PD; > H/M ratio (L) 2.8 or > 
AI-SBR 21.8%, classified as APD.
PD from nPD-nAPD are summarized in Table 3. 
 As for discriminating PD from APD, the scoring 
of each adapted parameter is shown in Table 4. For the 
MSS, the accuracy for discriminating PD from APD 
was 86% at a cutoff value of 2; PD diagnosis was indi-
cated by total score 2, 3, 4 or 5 and APD diagnosis was 
indicated by total score 0 or 1. The accuracy, sensitivity, 
specificity, positive predictive value and negative predic-
tive value of MSS in differentiating PD from APD are 
summarized in Table 4.
Evaluations of simple combined analysis for two statistical 
discriminations
As for discriminating PD from nPD-nAPD, WR and 
Ave-SBR were adapted for the simple combined anal-
ysis. The accuracy for discriminating PD from nPD-
nAPD was 70%. The cutoff value, accuracy, sensitivity, 
specificity, positive predictive value and negative predic-
tive value of the simple combined analysis in differenti-
ating PD from nPD-nAPD are summarized in Table 3.
 As for discriminating PD from APD, H/M ratio 
(delayed) and AI-SBR were adapted for the simple 
combined analysis. The accuracy for discriminating PD 
from APD was 80%. The cutoff value, accuracy, sensi-
tivity, specificity, positive predictive value and negative 
predictive value of the simple combined analysis in 
differentiating PD from APD are summarized in Table 4.
 Representative images of DAT-SPECT and MIBG 
myocardial scintigraphy for each group are shown in 
Fig. 2. 
DISCUSSION
This study evaluated whether combining DAT-SPECT 
and MIBG myocardial scintigraphy using the MSS 
could improve diagnostic accuracy in differentiating PD 
from non-PD; differentiating PD from nPD-nAPD and 
differentiating PD from APD. The analysis showed mild 
to moderate test accuracy for PD versus nPD-nAPD 
differentiation using each parameter alone [H/M ratio 
(early), 68%, H/M ratio (delayed), 70%, WR, 80%, Ave-
SBR, 70% and AI-SBR, 59%]. The highest accuracy 
resulted using MSS if at least 2 of the 5 parameters were 
positive for PD. MSS distinguished PD from nPD-nAPD 
with an accuracy of 84%. Also, the analysis showed 
mild to moderate test accuracy for PD versus APD 
differentiation using each parameter alone [H/M ratio 
(early), 82%, H/M ratio (delayed), 86%, WR, 80%, Ave-
SBR, 57% and AI-SBR, 77%]. The highest accuracy 
resulted using MSS if at least 2 of the 5 parameters were 
positive for PD. MSS distinguished PD from APD with 
an accuracy of 86%. In clinical terms, cases with PD are 
needed to be differentiated from non-PD. Combining 
DAT-SPECT and MIBG myocardial scintigraphy using 
this scoring system to discriminate PD from non-PD 
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with higher accuracy possibly provides additional value 
for the correct differentiation between PD and non-PD.
 DAT-SPECT is a sensitive modality to quantify the 
striatal density of dopamine transporters and detects 
nigrostriatal dysfunction due to cell loss at the substantia 
nigra. This method enables highly accurate differentia-
tion of PD from other parkinsonian disorders that are not 
associated with a dopamine deficit, namely nPD-nAPD.8 
For the discrimination of PD from nPD-nAPD in this 
study, the accuracy, sensitivity and specificity of Ave-
SBR were as high as 70%, 69% and 75%, respectively 
(P < 0.05). A recent meta-analysis study of DAT-SPECT 
revealed relatively high pooled sensitivity and specificity 
values of above 85% and 80% in differentiating between 
PD and vascular or drug-induced parkinsonism.34 The 
other hand, for the discrimination of PD from APD in 
this study, the accuracy, sensitivity and specificity of 
Ave-SBR were as high as 57%, 53% and 75%, respec-
tively (P > 0.05). DAT-SPECT is not enough for differ-
entiating between PD and APD because loss of dopami-
nergic neurons in the substantia nigra and reduction of 
striatal dopamine projections are the histopathological 
hallmarks in these disorders. Furthermore, mild to mod-
erate accuracy has been reported for distinguishing PD 
from degenerative parkinsonian syndromes.17, 20–22, 35
 It has been reported that the laterality of clinical 
symptoms in patients with PD contributes to the diag-
nosis of PD at an early stage.36, 37 On DAT-SPECT, the 
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Fig. 2. Example images of DAT-SPECT and MIBG 
myocardial scintigraphy (early and delayed) for nPD-
nAPD (A–C), APD (D–F), MM-PD (G–I) and S-PD 
(J–L) patients. (A–C) A 78-year-old man with vascular 
parkinsonian syndrome. Normal uptakes on both DAT-
SPECT (A) and MIBG myocardial scintigraphy [early in 
(B) and delayed in (C)]. Values of 6.66% (score 0) for the 
Ave-SBR, 3.6% (score 0) for the AI-SBR, 2.71 (score 0) 
for the H/M ratio (early), 3.1 (score 0) for the H/M ratio 
(delayed) and 11.2% (score 0) for the WR are scored as 
0 on MSS for discriminating nPD-nAPD from PD. The 
score 0 on MSS is correctly classified as nPD-nAPD. (D–
F) A 69-year-old man with PSP. Moderate low uptakes 
on DAT-SPECT (D) and normal uptakes on MIBG 
myocardial scintigraphy [early in (E) and delayed in (F)]. 
Values of 4.06% (score 0) for the Ave-SBR, 15.5% (score 
1) for the AI-SBR, 2.76 (score 0) for the H/M ratio (early), 
2.9 (score 0) for the H/M ratio (delayed) and 19.1% (score 
0) for the WR are scored as 1 on MSS for discriminating 
PD from APD. The score 1 on MSS is correctly classified 
as APD. (G–I) A 64-year-old woman with MM-PD. 
Moderate low uptakes on both DAT-SPECT (G) and 
MIBG myocardial scintigraphy [early in (H) and delayed 
in (I)]. Values of 5.89 % (score 0) for the Ave-SBR, 21.1% 
(score 1) for the AI-SBR, 1.98 (score 1) for the H/M ratio 
(early), 1.9 (score 1) for the H/M ratio (delayed) and 27.1% 
(score 1) for the WR are scored as 4 on MSS for discrim-
inating PD from APD. The score 4 on MSS is correctly 
classified as PD. (J–L) A 83-year-old man with S-PD. 
Severe low uptakes on both DAT-SPECT (J) and MIBG 
myocardial scintigraphy [early in (K) and delayed in (L)]. 
Values of 2.7 % (score 1) for the Ave-SBR, 0.4% (score 1) 
for the AI-SBR, 1.78 (score 1) for the H/M ratio (early), 
1.38 (score 1) for the H/M ratio (delayed) and 32.3% (score 
1) for the WR are scored as 5 on MSS for discriminating 
PD from APD. The score 5 on MSS is correctly classified 
as PD. 
AI, asymmetry index; APD, atypical parkinsonian 
disorder; Ave, average; DAT-SPECT, 123I-FP-CIT 
dopamine transporter single photon emission computed 
tomography; H/M, heart-to-mediastinum; 123I-FP-CIT, N-v-fluoro-propyl-2b-carbomethoxy-3b-(4-123I-iodophenyl)nortropane; MIBG, 
123I-metaiodobenzylguanidine; MM, mild to moderate; MSS, multiparametric scoring system; nPD-nAPD, parkinsonian syndromes 
other than PD or APD; PD, Parkinson’s disease; S, severe; SBR, specific binding ratio; WR, washout-rate.
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binding of ligands in the most affected side, which is the 
opposite side as the symptoms, results in a lower value. 
AI-SBR in DAT-SPECT is often used for differentiation 
between drug-induced or vascular parkinsonism and 
PD.38–40 In this study, for the discrimination of nPD-
nAPD from PD, the accuracy, sensitivity and speci-
ficity were as high as 59%, 53% and 88% (P = 0.05). 
Clinically, initial asymmetry in MM-PD decreases 
with the progression of the disease, and the value of AI-
SBR is reduced gradually. Therefore, AI-SBR is a good 
clinical indicator for diagnosing PD in the MM-PD, but 
not in S-PD.20, 23 The low accuracy in our study might be 
associated with the large number of cases with S-PD (20 
cases) in cases with PD (36 cases).
 In this study, we evaluated three parameters of 
MIBG myocardial scintigraphy; H/M ratio (early), H/
M ratio (delayed) and WR. For discriminating PD from 
nPD-nAPD, the accuracy was highest in WR (80%). For 
the WR, sensitivity and specificity for discriminating 
PD from nPD-nAPD were 83% and 63%, respectively. 
Also, for discriminating PD from APD, the accuracy 
was highest in H/M ratio (delayed) (86%). For the H/M 
ratio (delayed), sensitivity and specificity for discrimi-
nating PD from APD were 92% and 63%, respectively. 
The usefulness of MIBG myocardial scintigraphy in the 
diagnosis of Lewy body-related disorders was suggested 
recently in a meta-analysis. The sensitivity and specific-
ity of MIBG myocardial scintigraphy in the differential 
diagnosis between PD and non-PD ranged from 71 to 
100% and from 50 to 100%, respectively, with pooled 
estimates of 88% and 85%.39 Therefore, as many stud-
ies have indicated, MIBG myocardial scintigraphy is 
usually a sensitive, but not specific test for PD in terms 
of diagnostic performance.41–47 Ishibashi et al. reported 
that both the early and delayed images for the differ-
ential diagnosis between PD and non-PD showed high 
sensitivity in the advanced stage of PD and showed low 
sensitivity in the early stage of PD.48 In this study, the H/
M ratio (early and delayed) showed significantly lower in 
S-PD than in nPD-nAPD, APD and MM-PD. Therefore, 
MIBG myocardial scintigraphy seems to be useful for 
differentiation between non-PD and S-PD or between 
MM-PD and S-PD, but not useful for differentiation 
between non-PD and MM-PD.
 DAT-SPECT can assist the differentiation of degen-
erative parkinsonian syndromes from the other parkin-
sonian syndromes but is not capable of differentiating 
PD from APD. On the other hand, the accumulation is 
reduced in most PD cases on MIBG myocardial scintig-
raphy but is not capable of differentiating several MM-
PD cases from non-PD cases. Therefore, to overcome 
the shortcomings of each modality, the combination of 
DAT-SPECT and MIBG myocardial scintigraphy has 
been investigated for finding out PD in patients with par-
kinsonian syndrome.13–23 According to the recent studies, 
Yoshii et al. reported the combination of the SBR in 
DAT-SPECT and H/M ratio (delayed) in MIBG myo-
cardial scintigraphy, using cut off values of less than 4.5 
for the SBR and less than 2.2 for the H/M ratio (delayed) 
showed moderate accuracy (77.1%) in differentiating 
PD from APD.20 Uyama et al. reported the combination 
of the SBR in DAT-SPECT and H/M ratio (delayed) in 
MIBG myocardial scintigraphy, using cut off values of 
less than 3.24 for the SBR and less than 2.745 for the H/
M ratio (delayed) showed moderate accuracy (79.4%) in 
differentiating PD from APD.21 
 In this study, we compared the test accuracies of 
five parameters, a MSS and a simple combined analysis 
in each of the two statistical discriminations. As for 
discriminating PD from APD, the highest accuracy of 
five parameters was 86% for the H/M ratio (delayed). 
The analysis of MSS using five parameters showed the 
highest accuracy (86%) resulted if at least 2 of the 5 pa-
rameters were positive for PD, using the following cutoff 
values: H/M ratio (early), 2.51; H/M ratio (delayed), 2.8; 
WR, 22%; Ave-SBR, 3.31; and AI-SBR, 21.8. For the 
simple combined analysis using the best accuracy in 
each DAT-SPECT and MIBG myocardial scintigraphy; 
H/M ratio (delayed) and AI-SBR, the accuracy for 
discriminating PD from APD was 80%. As for discrim-
inating PD from nPD-nAPD, the highest accuracy of 
five parameters was 80% for the WR. The analysis of 
MSS using five parameters showed the highest accuracy 
(84%) resulted if at least 2 of the 5 parameters were 
positive for PD, using the following cutoff values: H/
M ratio (early), 2.1; H/M ratio (delayed), 1.9; WR, 19%; 
Ave-SBR, 4.29%; and AI-SBR, 16.9%. For the simple 
combined analysis using the best accuracy in each DAT-
SPECT and MIBG myocardial scintigraphy; WR and 
Ave-SBR, the accuracy for discriminating PD from 
nPD-nAPD was 70%. Hence, on the analysis combining 
DAT-SPECT and MIBG myocardial scintigraphy, MSS 
using five parameters had better accuracy compared to 
the simple combined analysis using two parameters in 
discriminating PD from non-PD. 
 The reason MSS was superior to the simple com-
bined analysis remains unclear. For the analysis using 
MSS, 3 of the 5 parameters [H/M ratio (early and 
delayed) and WR] were used for the evaluation of the 
postganglionic sympathetic function, and 2 of the 5 
parameters (Ave-SBR and AI-SBR) were used for the 
evaluation of the nigrostriatal dopaminergic system. The 
highest accuracy resulted using MSS if at least 2 of the 5 
parameters were positive for PD in both discriminating 
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PD from nPD-nAPD and discriminating PD from APD. 
The other hand, for the simple combined analysis using 
two parameters; parameters with the best accuracy in 
each DAT-SPECT and MIBG myocardial scintigraphy, 
one was used for the evaluation of the postganglionic 
sympathetic function and another was used for the 
evaluation of the nigrostriatal dopaminergic system. 
Therefore, on the simple combined analysis using two 
parameters, cases with PD seemed to be correctly 
categorized by the combination of both dysfunctions 
whereas on the MSS using five parameters, cases with 
PD were correctly categorized not only by the combina-
tion of both dysfunctions but also by only sympathetic 
dysfunctions or only nigrostriatal dopaminergic dys-
functions.  
 Our study has several limitations. First, this study 
was carried out in a single hospital; thus, the study 
population was small. Second, we evaluated PD and 
various other parkinsonian syndromes, including APD, 
Alzheimer disease, essential tremor and vascular par-
kinsonian syndrome, because we attempted to evaluate 
cases with overall parkinsonian syndromes. Third, the 
clinical diagnosis was used as the gold standard in our 
study because of the absence of histopathological con-
firmation. Fourth, according to the official International 
Parkinson and Movement Disorder Society clinical 
diagnostic criteria for Parkinson’s disease (MDS-PD 
criteria), the supportive criteria include abnormal finding 
on MIBG myocardial scintigraphy although the abso-
lute exclusion criteria include normal finding of DAT-
SPECT.49 Therefore, it should be noted that abnormal 
finding of DAT-SPECT was used supportively in this 
study, unlike in MDS-PD criteria, because abnormal 
findings of both DAT-SPECT and MIBG myocardial 
scintigraphy were used for discriminating PD from non-
PD in this study. Because of these limitations, the results 
of this study should be considered a preliminary pilot 
investigation. Further validation is needed with a larger 
number of cases. However, this evaluation method using 
MSS is expected to be a useful indicator for differentiat-
ing PD from other parkinsonian syndromes.
 In conclusion, combining MIBG myocardial scintig-
raphy and DAT-SPECT results using a MSS has poten-
tial to improve diagnostic accuracy in distinguishing PD 
from non-PD.
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